An example is found in the unique association of myeloid and/or suppressor signatures with HD-IL2 responders, which potentially could be exploited to select patients that are ideally suited for treatment with IL2 or combination of IL2 and anti-PD-(L)1. Here, IL2 is linked to Huntington disease.